Aktie A298380 ABL BIO INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen ABL Bio Inc.

Aktien

A298380

KR7298380007

A298380

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 21.05.2024 		% 5 Tage % 1. Jan.
25 400 KRW -0,59 % Intraday Chart für ABL Bio Inc. +5,61 % +3,25 %
25.03. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. geht Zusammenarbeit mit ABL Bio Inc. zur Entwicklung neuer bispezifischer Antikörper-Wirkstoff-Konjugate ein CI
2023 ABL Bio Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen and ABL Bio enter into a collaboration to jointly develop new dual-antibody ADC drugs
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates
ABL Bio Taps into Synaffix ADC Technology
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific
Genscript Biologics Enters into an Agreement with ABL Bio Inc
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A298380 Aktie
  4. Nachrichten ABL Bio Inc.
  5. Andere Sprachen